Baird Medical said Tuesday it has relocated its global headquarters to New York City, setting up a corporate office that will serve as the central hub for its U.S. commercial expansion. The move comes as the company builds a U.S. sales force and establishes manufacturing partnerships to accelerate adoption of its minimally invasive microwave ablation platform. Company leaders say the shift to New York should give them easier access to healthcare investors and clinical partners across the country.
In a press release via PR Newswire, Baird Medical (NASDAQ: BDMD) said the New York office "will serve as a central hub for corporate leadership and strategic initiatives" and quoted U.S. CEO Mark Saxton as saying the relocation provides "more efficient access to the world's most sophisticated healthcare investors." The release also quoted Chairwoman and CEO Haimei Wu saying the company's U.S. operational buildout is "progressing on schedule."
What the move means for U.S. rollout
Mark Saxton, who was named chief executive of Baird Medical's U.S. subsidiary in December 2025, will lead sales, marketing and market development as the company presses into American hospitals. Saxton is a 25‑year medtech veteran whose resume includes stints at NeuroPace, Covidien and Smith & Nephew, experience Baird leaders say is critical to scaling operations. As reported by CityBiz, Saxton told investors he sees significant opportunity for microwave ablation in the U.S.
Manufacturing and clinical footprint
Baird has been building out production and clinical programs ahead of the commercial push: the company describes itself as an FDA 510(k)-certified medical device maker with its systems used at more than 30 U.S. hospitals, and it says it is expanding into more than 20 countries. The company also established a North American production hub through a partnership designed to support U.S. commercialization and product supply, as detailed in its April 29 corporate update. These operational details were outlined on Nasdaq and in the company's investor materials.
What to watch next
Baird Medical reported $22.5 million in revenue for 2025 and has signaled it will lean on U.S. manufacturing partners and physician education to grow adoption, per its April 29 update. The company trades on Nasdaq as BDMD; more corporate and financial detail is available in its Form 20-F filing. See the company filing for full details: Form 20-F.
